Dublin, Aug. 16, 2024 (GLOBE NEWSWIRE) -- The "Pericarditis Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The global market for Pericarditis Drugs is estimated at US$3.7 Billion in 2023 and is projected to reach US$4.7 Billion by 2030, growing at a CAGR of 3.5% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The report forecasts significant growth in the Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) segment, which is expected to reach $2.5 billion by 2030 with a CAGR of 3.7%. The Colchicine Drugs segment is also projected to grow at a 2.8% CAGR over the analysis period. In the regional analysis, the U.S. market is estimated at $1.0 billion in 2023, while China is forecasted to grow impressively at a 6.7% CAGR, reaching $969.0 million by 2030. The report also highlights growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
It provides comprehensive market data, including independent analysis of annual sales and forecasts in USD from 2023 to 2030. Additionally, the report offers detailed regional insights and company profiles of major players like AbbVie Inc., Amneal Pharmaceuticals LLC, and Aurobindo Pharma Ltd. Subscribers will benefit from complimentary updates for one year to stay informed on the latest market developments.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 289 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value (USD) in 2023 | $3.7 Billion |
| Forecasted Market Value (USD) by 2030 | $4.7 Billion |
| Compound Annual Growth Rate | 3.5% |
| Regions Covered | Global |
MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Global Economic Update
- Pericarditis Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
MARKET TRENDS & DRIVERS
- Increasing Incidence of Cardiac Disorders Driving Demand for Pericarditis Treatment
- Advances in Targeted Therapy for Autoimmune-Related Pericarditis
- Development of Novel Anti-inflammatory Drugs
- Patient Awareness and Growing Demand for Early Treatment
- Challenges in Diagnosis and Treatment of Recurrent Pericarditis
- Regulatory Support for Fast-Tracking Critical Cardiovascular Drugs
- Adoption of Combination Therapies for Enhanced Treatment Outcomes
- Research Funding for Cardiovascular Diseases Influencing Market Dynamics
- Technological Advances in Diagnostic Methods for Early Detection
- Patent Expiries and the Surge of Generics in the Market
- Strategic Alliances Among Biopharmaceuticals for Drug Development
- Global Initiatives to Reduce Burden of Cardiovascular Diseases
- Impact of Lifestyle Changes on Incidence and Management of Pericarditis
- Integration of Pharmacogenomics in Personalized Medication
- Growing Role of AI in Clinical Trials and Drug Development
FOCUS ON SELECT PLAYERS(Total 52 Featured)
- AbbVie Inc.
- Amneal Pharmaceuticals LLC
- Aurobindo Pharma Ltd.
- Bayer AG
- Bristol-Myers Squibb Company
- Cardiol Therapeutics Inc.
- Dr. Reddy`s Laboratories Ltd
- Hikma Pharmaceuticals plc
- Johnson & Johnson Services, Inc.
- Kiniksa Pharmaceuticals Corp.
- Lupin Pharmaceutical, Inc.
- Novartis International AG
- Takeda Pharmaceutical Co. Ltd
- Teva Pharmaceutical Industries Ltd (Israel)
- Viatris Inc
For more information about this report visit https://www.researchandmarkets.com/r/o06lt6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
